Orega Biotech
OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered with AstraZeneca (2018). It is currently in phase 2 clinical trial in NSCLC. The second program, at preclinical stage, targets a new regulator of the immune response in order to overcome resistance to anti-PD1 antibodies. The investors are initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
6
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Orega Biotech
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Orega Biotech
3 distinct titles indexed · top 3 shown.
- 1administrative manager
- 1directeur général
- 1responsable de laboratoire et des études de preuves de concept
Sign up to unlock all 3 contacts at Orega Biotech
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Orega Biotech
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.